| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net loss | ||||||
-40,796 | -31,536 | -27,019 | -23,173 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization expense | ||||||
3,009 | 1,352 | 482 | 444 | |||
Inventory step-up amortization | ||||||
611 | - | - | - | |||
Stock-based compensation expense | ||||||
6,388 | 4,884 | 2,168 | 928 | |||
Non-cash interest expense | ||||||
89 | 170 | 238 | 388 | |||
Loss on disposal of fixed assets | ||||||
-140 | 14 | - | -11 | |||
Non-cash research and development expense for issuance of warrants to a vendor | ||||||
- | - | - | 2,078 | |||
Change in fair value of preferred stock warrants | ||||||
- | - | 90 | 307 | |||
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
3,365 | 983 | 1,682 | 1,655 | |||
Deposits | ||||||
- | - | - | 200 | |||
Prepaid expenses and other assets | ||||||
-289 | 1,828 | 273 | -6 | |||
Inventory | ||||||
3,447 | 1,603 | 2,043 | 526 | |||
Other non-current assets | ||||||
21 | -267 | - | - | |||
Accounts payable | ||||||
621 | 1,318 | 1,003 | 1,131 | |||
Accrued compensation and benefits, other accrued expenses and other current liabilities | ||||||
822 | 1,101 | 2,035 | 1,200 | |||
Contract acquisition costs | ||||||
336 | - | - | - | |||
Other non-current liabilities | ||||||
9,845 | - | - | - | |||
Deferred revenue | ||||||
-708 | -1,849 | 2,895 | 919 | |||
Net cash used in operating activities | ||||||
-26,187 | -28,721 | -22,106 | -17,742 | |||
Investing activities | ||||||
Purchases of property and equipment | ||||||
10,847 | 1,518 | 1,132 | 526 | |||
Purchase of investments | ||||||
- | 150 | - | - | |||
Acquisition of UmanDiagnostics AB, net of cash acquired | ||||||
14,529 | 3,801 | - | 300 | |||
Proceeds from sale of assets | ||||||
- | 15 | - | - | |||
Net cash used in investing activities | ||||||
-25,376 | -5,454 | -1,132 | -826 | |||
Financing activities | ||||||
Proceeds from sale of preferred stock, net of issuance costs | ||||||
- | - | 65,575 | - | |||
Proceeds from sale of common stock, net of issuance costs | ||||||
- | -20 | 8,423 | 45,428 | |||
Proceeds from exercise of stock warrants | ||||||
- | - | 29 | 18 | |||
Proceeds from stock options exercised | ||||||
2,820 | 1,871 | 202 | 213 | |||
Proceeds from ESPP purchase | ||||||
879 | - | - | - | |||
Proceeds from the issuance of notes payable and warrants, net of issuance costs | ||||||
- | - | -59 | 2,954 | |||
Payments on notes payable | ||||||
50 | 1,929 | 921 | 2,697 | |||
Net cash provided by financing activities | ||||||
116,197 | -78 | 73,249 | 45,916 | |||
Net decrease in cash and cash equivalents | ||||||
64,634 | -34,253 | 50,011 | 27,348 | |||
Effect of foreign currency exchange rate on cash | ||||||
118 | - | - | - | |||
Supplemental cash flow information | ||||||
Accretion of preferred stock to redemption value | ||||||
- | - | 4,110 | 4,437 | |||
Cash paid for interest | ||||||
656 | 606 | 743 | 945 | |||
Warrants issued to lenders | ||||||
- | - | 119 | 128 | |||
Purchases of property and equipment included in accounts payable | ||||||
164 | 78 | - | 72 | |||
191,152 shares of common stock issued in connection with the acquisition of UmanDiagnostics AB | ||||||
5,468 | - | - | - | |||
Purchases of property and equipment included in other non-current liabilities | ||||||
7,572 | - | 74 | - | |||
Fair value of common stock warrants exercised and reclassified as shares of common stock | ||||||
- | 196 | 2,187 | 5,257 | |||
At-the-market offering | ||||||
Proceeds from sale of common stock, net of issuance costs | ||||||
48,019 | - | - | - | |||
Underwritten public offering | ||||||
Proceeds from sale of common stock, net of issuance costs | ||||||
64,529 | - | - | - | |||